SOPHiA GENETICS is proud to participate in the 50th National Congress of the Mexican Association of Human Genetics (AMGH) and the 9th Latin American Congress of Human Genetics, organized by AMGH and the Red Latinoamericana de Genética Humana.
📅 November 12–14, 2025
📍 Hotel Sheraton Buganvilias, Puerto Vallarta, Jalisco, Mexico
As a global leader in data-driven medicine, we are thrilled to join this milestone event, bringing together experts, researchers, and clinicians from across Latin America.
📍 Visit us at Booth 6
Our team will be on-site to showcase how the SOPHiA DDM™ Platform transforms complex genomic data into actionable insights—empowering healthcare professionals to accelerate discovery, enhance diagnosis, and drive precision medicine forward.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.